JP2011520781A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520781A5
JP2011520781A5 JP2011503360A JP2011503360A JP2011520781A5 JP 2011520781 A5 JP2011520781 A5 JP 2011520781A5 JP 2011503360 A JP2011503360 A JP 2011503360A JP 2011503360 A JP2011503360 A JP 2011503360A JP 2011520781 A5 JP2011520781 A5 JP 2011520781A5
Authority
JP
Japan
Prior art keywords
cell
egf
ms4a12
activity
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011503360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520781A (ja
Filing date
Publication date
Priority claimed from EP08007109A external-priority patent/EP2108701A1/en
Application filed filed Critical
Publication of JP2011520781A publication Critical patent/JP2011520781A/ja
Publication of JP2011520781A5 publication Critical patent/JP2011520781A5/ja
Pending legal-status Critical Current

Links

JP2011503360A 2008-04-10 2009-03-30 治療、診断及び検査のためのms4a12を伴う方法、及びms4a12を標的とする剤 Pending JP2011520781A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08007109.5 2008-04-10
EP08007109A EP2108701A1 (en) 2008-04-10 2008-04-10 Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
PCT/EP2009/002309 WO2009124670A1 (en) 2008-04-10 2009-03-30 Methods involving ms4a12 and agents targeting ms4a12 for therapy, diagnosis and testing

Publications (2)

Publication Number Publication Date
JP2011520781A JP2011520781A (ja) 2011-07-21
JP2011520781A5 true JP2011520781A5 (cg-RX-API-DMAC7.html) 2012-05-24

Family

ID=39811474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011503360A Pending JP2011520781A (ja) 2008-04-10 2009-03-30 治療、診断及び検査のためのms4a12を伴う方法、及びms4a12を標的とする剤

Country Status (8)

Country Link
US (1) US20110027297A1 (cg-RX-API-DMAC7.html)
EP (2) EP2108701A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011520781A (cg-RX-API-DMAC7.html)
CN (1) CN101998992A (cg-RX-API-DMAC7.html)
AU (1) AU2009235746A1 (cg-RX-API-DMAC7.html)
CA (1) CA2714997A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ588177A (cg-RX-API-DMAC7.html)
WO (1) WO2009124670A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263714B1 (en) * 2015-02-24 2021-08-25 Theoria Science Inc. Method for diagnosing brain metastasis
CN109562379A (zh) 2016-06-20 2019-04-02 拜克门寇尔特公司 用于染料共轭试剂的干燥过程
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
EP3746484A4 (en) 2018-01-31 2021-11-17 Alector LLC ANTI-MS4A6A ANTIBODIES AND PROCESSES FOR USE
WO2021022083A2 (en) * 2019-07-31 2021-02-04 Alector Llc Anti-ms4a4a antibodies and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
DE60140676D1 (de) 2000-03-30 2010-01-14 Massachusetts Inst Technology Mediatoren von rns-interferenz, die rns-sequenzspezifisch sind
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10341812A1 (de) * 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung

Similar Documents

Publication Publication Date Title
Reid et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer
Guo et al. Exosomes: Potent regulators of tumor malignancy and potential bio-tools in clinical application
Icli et al. MicroRNA-135a-3p regulates angiogenesis and tissue repair by targeting p38 signaling in endothelial cells
Yang et al. Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications
Li et al. Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure
Shen et al. Post‐transcriptional regulation of the tumor suppressor miR‐139‐5p and a network of miR‐139‐5p‐mediated m RNA interactions in colorectal cancer
Yao et al. Down-regulation of Krüppel-like factor-4 by microRNA-135a-5p promotes proliferation and metastasis in hepatocellular carcinoma by transforming growth factor-β1
Matsumoto et al. Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma
JP2014526456A5 (cg-RX-API-DMAC7.html)
EP3111937A1 (en) Medicament for treatment of liver cancer
Zhu et al. eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma
JP2016540778A5 (cg-RX-API-DMAC7.html)
Pathak et al. Role of angiogenesis and its biomarkers in development of targeted tumor therapies
CA2946407A1 (en) Multiple targeted rnai for the treatment of cancers
Han et al. TUG1 is involved in liver fibrosis and activation of HSCs by regulating miR-29b
JP2014526450A5 (cg-RX-API-DMAC7.html)
Wang et al. Human cancer cells suppress behaviors of endothelial progenitor cells through miR-21 targeting IL6R
JP2011520781A5 (cg-RX-API-DMAC7.html)
Takiguchi et al. Involvement of CXCL14 in osteolytic bone metastasis from lung cancer
EP3301176B1 (en) Method for identifying nucleic acids regulating metastasation
JP2014523398A5 (cg-RX-API-DMAC7.html)
Hu et al. Interruption of the long non-coding RNA HOTAIR signaling axis ameliorates chemotherapy-induced cachexia in bladder cancer
Zhou et al. Long noncoding RNA ZFAS1 promotes hepatocellular carcinoma proliferation by epigenetically repressing miR-193a-3p.
Jalink et al. Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction
Luo et al. The function and clinical relevance of lncRNA UBE2CP3-001 in human gliomas